Prognosis of Troponin-Positive Patients with Non-Obstructive Coronary Artery Disease
Tóm tắt
Troponin elevation is an independent risk factor for mortality, but the prognosis of patients with troponin elevation and non-obstructive coronary artery disease (CAD) is unknown. Recent data have suggested an increased risk of mortality. This study was performed to further investigate the outcomes of troponin-positive patients with obstructive and non-obstructive CAD. A retrospective cohort analysis was performed of all patients with raised troponin presenting to Kettering General Hospital (January 2010 to December 2011, n = 1,351). The patients who had angiograms were stratified anatomically into obstructive CAD and non-obstructive CAD (≤50% stenosis). The obstructive CAD group (O-CAD) was sub-analyzed by management strategy: emergency re-vascularization (<12 h), urgent, delayed, and medically managed. Patients with non-obstructive CAD were grouped by the cause of the raised troponin if this could be identified (NO-CAD-I) or cause remained unidentified (NO-CAD-U). The major adverse cardiac and cerebrovascular event (MACCE) and mortality rates were calculated at 30 days and 1-year follow-up. There was a preponderance of hypertension and severe renal impairment in the non-obstructive CAD group. The patients with NO-CAD-U were a low-risk group (MACCE at 1-year follow-up = 0). The remaining NO-CAD-I group had a similar risk to the O-CAD group for MACCE and mortality at 30 days and 1-year follow-up. In fact, at 1-year follow-up, the NO-CAD-I patients when compared with the subgroups of O-CAD, had higher MACCE rates and mortality compared with the emergency re-vascularized group [MACCE: relative risk (RR) (95% CI) = 2.27 (1.29–3.40), P = 0.0047; mortality: RR (95% CI) = 2.08 (1.10–3.93), P = 0.024]. This was driven by higher risk non-cardiac death [RR (95% CI) = 4.10 (1.53–10.99), P = 0.005]. Patients with identified cause for raised troponin and non-obstructive CAD are at equivalent risk of MACCE and mortality at 30 days and 1-year follow-up compared to those with obstructive CAD.
Tài liệu tham khảo
Agewall S, Giannitsis E, Jernberg T, et al. Troponin elevation in coronary vs. non-coronary disease. Eur Heart J. 2011;32:404–11.
Esther AP, Bockel V, Tulleken JE, et al. Troponin in septic and critically ill patients. Chest. 2005;127:687–8.
Roongsritong C, Warraich I, Bradley C. Common causes of troponin elevations in the absence of acute myocardial infarction—incidence & clinical significance. Chest. 2004;125:1877–84.
Mehta S, Morales PF, Pillai M, et al. Prognostic implications of elevated troponin in patients with suspected acute coronary syndrome with non- obstructive coronary artery disease. Circulation. 2007;116:624.
Planer D, Lincoff AM, Moses JW, et al. Prognosis of patients presenting with acute coronary syndromes with elevated serum troponins & non-obstructive coronary artery disease: the ACUITY trial. JACC. 2011;58:387.
Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. 1996;335:1342–9.
Florkowski CM, Chew-Harris JSC. Methods of estimating GFR-Different equations including CKD-EPI. Clin Biochem Rev. 2011;32:75–9.
Jeremias A, Gibson CM. Narrative review: alternative causes for elevated cardiac troponin levels when acute coronary syndromes are excluded. Ann Intern Med. 2005;142:786–91.
Heidenreich PA, Alloggiamento T, Melsop K, et al. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a metaanalysis. J Am Coll Cardiol. 2001;38:478–85.
Dokainish H, Pillai M, Murphy SA, et al. Prognostic implications of elevated troponin in patients with suspected acute coronary syndrome but no critical epicardial coronary disease, a TACTICS-TIMI-18 Sub-study. JACC. 2005;45:19–24.
Myint PK, Al-Jawad M, Chacko SM, et al. Prevalence, characteristics and outcomes of people aged 65 years and over with an incidental rise in cardiac troponin I. Cardiology. 2008;110:62–7.
Collinson PO. Sensitive troponin assays. Postgrad Med J. 2012;88:348–52.
Nikhilesh J, Sathyamurthy I. Troponins: current status in coronary artery disease. J Assoc Phys India. 2005;53:116–8.
Maeder M, Fehr T, Rickli H, et al. Sepsis-associated myocardial dysfunction: diagnostic and prognostic impact of cardiac troponins and natriuretic peptides. Chest. 2006;129:1349–66.
Skeik N, Patel DC. A review of troponins in ischemic heart disease and other conditions. Int J Angiol. 2007;16:53–8.
Hamm CW, Bassand J-P, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2011;32:2999–3054.
Segev A, Beigel R, Goitein O, et al. Non-obstructive coronary artery disease upon multi-detector computed tomography in patients presenting with acute chest pain—results of an intermediate term follow-up. Eur Heart J Cardiovasc Imaging. 2012;13:169–73.
Ohlmann P, Kim SW, Mintz GS, et al. Cardiovascular events in patients with coronary plaque rupture and non-significant stenosis. Am J Cardiol. 2005;96:1631–5.
Ammann P, Maggiorini M, Bertel O, et al. Troponin as a risk factor for mortality in critically ill patients without acute coronary syndromes. J Am Coll Cardiol. 2003;41:2004–9.
Al-Otaiby MA, Al-Amri HS, Al-Moghairi AM. The clinical significance of cardiac troponins in medical practice. J Saudi Heart Assoc. 2011;23:3–11.
DeFilippi C, Wasserman S, Rosanio S, et al. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA. 2003;290:353–9.
Alcalai R, Planer D, Culhaoglu A, et al. Acute coronary syndrome vs nonspecific troponin elevation. Arch Intern Med. 2007;167:276–81.
Patil H, Vaidya O, Bogart D. A review of causes and systemic approach to cardiac troponin elevation. Clin Cardiol. 2011;34:723–8.